Company intelligence / Profile preview

LamKap Bio beta

Schaffhausen, Schaffhausen, Switzerland

Ownership: Private
Development stage: Other

Overview

LamKap Bio beta is a Swiss biotechnology company focused on the development of next-generation immuno-oncology therapies. As a member of the LamKap Bio group, the company operates under an asset-centric model, specifically dedicated to advancing therapeutic candidates targeting B7-H3 (CD276). B7-H3 is a checkpoint target that is highly expressed across various solid tumors and is associated with tumor progression and immune evasion. The company leverages advanced antibody engineering to create potent molecules designed to improve clinical outcomes for patients with treatment-resistant cancers.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyBispecific monoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on LamKap Bio beta.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LamKap Bio beta.

Explore the full profile